Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-061817
Filing Date
2025-05-01
Accepted
2025-05-01 16:05:29
Documents
87
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q alks-20250331.htm   iXBRL 10-Q 2526383
2 EX-31.1 alks-ex31_1.htm EX-31.1 19368
3 EX-31.2 alks-ex31_2.htm EX-31.2 19383
4 EX-32.1 alks-ex32_1.htm EX-32.1 24386
5 GRAPHIC img78440924_0.jpg GRAPHIC 13021
6 GRAPHIC img78440924_1.jpg GRAPHIC 134869
7 GRAPHIC img78440924_2.jpg GRAPHIC 140207
8 GRAPHIC img78440924_3.jpg GRAPHIC 66302
  Complete submission text file 0000950170-25-061817.txt   12064467

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alks-20250331.xsd EX-101.SCH 1501104
90 EXTRACTED XBRL INSTANCE DOCUMENT alks-20250331_htm.xml XML 2296525
Mailing Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000
Business Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000 00-353-1-772-8000
Alkermes plc. (Filer) CIK: 0001520262 (see all company filings)

EIN.: 981007018 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35299 | Film No.: 25902988
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)